



## Defining the Nature of Neurological Complications after COVID-19 Vaccines

Guest Editor:

**Dr. Maria Salsone**

Institute of Molecular Bioimaging  
and Physiology, National  
Research Council, Milan, Italy

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editor

Dear Colleagues,

COVID-19 pandemic has affected millions of people and imposed new scientific priorities. Several vaccines are approved for the use in multiple countries, showing to reduce COVID-19 infections and transmissions, number of hospitalizations and deaths in randomized controlled trials and effectiveness studies. The use of the vaccines shown rare adverse event including several potentially serious neurological complications, such as cortical sinus venous thrombosis, Bell's palsy, transverse myelitis and Guillain-Barré syndromes, leading to public concerns. Thus, the mass vaccination campaigns against COVID-19 infection sounds as an urgent call for researchers to independently assess the safety profile of vaccines in different populations and noncontrolled settings.

Based on your extensive knowledge and clinical experience, we invite scholars to submit their work on the collected evidence (original report, original observation or review) to provide more clarity and knowledge regarding the occurrence and severity of the post-vaccination neurological implications.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)